With the midterms behind them, health system leaders say coverage losses, thin margins, and payer fights are coming no matter ...

Resmetirom real-world data at The Liver Meeting 2026 show 12-month gains in liver stiffness, fat, and enzymes among patients ...

Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was ...

A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term ...

Most hospitalized COPD flare-ups aren't severe by bedside criteria, experts say, and a tiered testing bundle could guide ...

The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election require ...

Harvard Medical School’s Emily S. Wan, MD, discusses mucus plugs in COPD, how to detect them, and what would make them a treatment target.

Senator Andy Kim (D, New Jersey) discusses plans to reverse Medicaid cuts and make caregiving a priority in the next Congress ...

Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap ...

Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded ...

The University of Exeter’s David Halpin, MA, DPhil, discusses inhaler device selection, single vs multiple inhalers, and the pharmacist’s role in COPD.

No systemic scalp psoriasis therapy raised serious adverse event risk in a network meta-analysis; only apremilast increased discontinuation.